[HTML][HTML] Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes
SA Long, J Thorpe, KC Herold, M Ehlers, S Sanda… - Cellular …, 2017 - Elsevier
The immunological mechanism (s) of action whereby teplizumab preserves C-peptide levels
in the progression of patients with recent onset type 1 diabetes (T1D) is still not well
understood. In the present study, we evaluated the kinetics of T cell modulation in peripheral
blood following two 14-day courses of teplizumab therapy one year apart in recent onset
T1D participants in the AbATE clinical trial. Transient rises in PD-1+ Foxp3+ Treg and
potentially anergic (CD57− KLRG1− PD-1+) cells in the circulating CD4 T cell compartment …
in the progression of patients with recent onset type 1 diabetes (T1D) is still not well
understood. In the present study, we evaluated the kinetics of T cell modulation in peripheral
blood following two 14-day courses of teplizumab therapy one year apart in recent onset
T1D participants in the AbATE clinical trial. Transient rises in PD-1+ Foxp3+ Treg and
potentially anergic (CD57− KLRG1− PD-1+) cells in the circulating CD4 T cell compartment …
